Nasdaq
$15.68▲ 0.26%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.54BShares out 98.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 4d agoAfter-hours26.10.21 06:37SCHEDULE 13GOwnership#●●●#●●●
Ultragenyx Pharmaceutical Inc.
A group of investors including Madison Avenue International LP filed a Schedule 13G regarding their stake in Ultragenyx Pharmaceutical Inc. on October 20, 2026. The investors, managed by Eli Samaha, have entered into a joint filing agreement in accordance with regulatory requirements.…more
$15.68+0.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoRegular26.10.20 02:484Ownership
Ultragenyx Pharmaceutical Inc.
Howard Horn, an executive at Ultragenyx Pharmaceutical, reported a change in his beneficial ownership of company securities as of October 15, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock holdings.…more
$15.68+0.26%vs prev closeView filingShare - 6d agoPre-market26.10.19 22:008-KKey event
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical has entered into a settlement agreement with Navinta LLC to resolve patent litigation concerning its DOJOLVI product. Under the terms, Navinta is granted a non-exclusive, royalty-free license to market a generic version of DOJOLVI starting January 1, 2033.…more
$15.68+0.26%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 22:11#●●●
Ultragenyx Settles DOJOLVI Patent Litigation, Sets Generic Entry for 2033…more
Ultragenyx has reached a settlement with Navinta regarding DOJOLVI patent litigation, allowing a generic version to enter the market in 2033. However, similar patent litigation against other generic applicants remains ongoing.…more
$15.68+0.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 21:30
●●●●●●●● ●●●●● ●●●●●●
Ultragenyx has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. The company plans to use these non-dilutive proceeds to support its pipeline and path to profitability.…more
$15.68+0.26%vs prev close - 10.7Pre-market26.10.07 21:30
●●●●●●●● ●●●●● ●●●●●●
Ultragenyx Pharmaceutical has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $210 million. The company plans to use the non-dilutive capital to advance its rare disease pipeline and support its path to profitability.…more
$15.68+0.26%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report